Abstract Connexin 43 (Cx43), the most widely expressed and abundant vertebrate gap junction protein, is phosphorylated at multiple different serine residues during its life cycle. Cx43 is phosphorylated soon after synthesis and phosphorylation changes as it traffics through the endoplasmic reticulum and Golgi to the plasma membrane, ultimately forming a gap junction structure. The electrophoretic mobility of Cx43 changes as the protein proceeds through its life cycle, with prominent bands often labeled P0, P1 and P2. Many reports have indicated changes in ''phosphorylation'' based on these mobility shifts and others that occur in response to growth factors or other biological effectors. Here, we indicate how phosphospecific and epitope-specific antibodies can be utilized to show when and where certain phosphorylation events occur during the Cx43 life cycle. These reagents show that phosphorylation at S364 and/or S365 is involved in forming the P1 isoform, an event that apparently regulates trafficking to or within the plasma membrane. Phosphorylation at S325, S328 and/or S330 is necessary to form a P2 isoform; and this phosphorylation event is present only in gap junctions. Treatment with protein kinase C activators led to phosphorylation at S368, S279/S282 and S262 with a shift in mobility in CHO, but not MDCK, cells. The shift was dependent on mitogen-activated protein kinase activity but not phosphorylation at S279/S282. However, phosphorylation at S262 could explain the shift. By defining these phosphorylation events, we have begun to sort out the critical signaling pathways that regulate gap junction function.
Introduction
Gap junctions are collections of intercellular channels that directly connect the cytoplasmic contents of adjacent cells. They coordinate cell-to-cell communication within tissues by allowing for the transfer of molecules less than 1,000 daltons between cells, including ions, amino acids, nucleotides, second messengers (e.g., Ca 2+ , cyclic adenosine monophosphate, cyclic guanosine monophosphate, inositol 1,4,5-trisphosphate) and other metabolites (Loewenstein & Azarnia, 1988; Saez et al., 2003; Simon, Goodenough & Paul, 1998; Willecke et al., 2002) . In vertebrates, gap junctions are composed of proteins from the connexin family, which is composed of 21 members in humans (Goodenough & Paul, 2003; Saez et al., 2003; Sohl & Willecke, 2004) . Connexins are commonly designated with numerical suffixes referring to the molecular weight of the deduced sequence in kilodaltons (e.g., connexin43 or Cx43) (Saez et al., 2003; Sohl & Willecke, 2004) . Connexins are differentially expressed in tissues, with some being significantly expressed in only a few tissues and some, like Cx43, being more widespread. Gap junctions play significant regulatory roles in embryonic development, electrical coupling, apoptosis, differentiation, tissue homeostasis and metabolic transport (Goodenough & Paul, 2003; Loewenstein & Azarnia, 1988; Sohl & Willecke, 2004) .
Cx43 electrophoreses as multiple isoforms when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), including a faster-migrating form that includes nonphosphorylated (P0 or NP) Cx43 and at least two slower-migrating forms, commonly termed P1 and P2 (Crow et al., 1990; Musil et al., 1990) . Pulse-chase analysis indicated that the Cx43 isoforms progress from P0 to P1 to P2 and that the P2 isoform is associated with gap junctional structures (Musil & Goodenough, 1991) . Cx43 is critical for the synchronous beating of cardiac tissue. Gap junctions composed of Cx43 are localized to intercalated disks in the ventricle, where they support the longitudinal spread of the action potential resulting in coordinated contraction. When cardiac tissue is immunoblotted for Cx43, only slower-migrating ''phosphorylated'' isoforms are observed. Myocardial ischemia leads to Cx43 ''dephosphorylation'' (i.e., loss of P1, P2, etc. and gain of P0) and loss of localization from the intercalated disk, which likely contributes to contractile failure and arrhythmias (Beardslee et al., 2000; Schulz et al., 2003) . We have shown that Cx43 localized to intercalated disks is phosphorylated at S325, S328 and/or S330 and that ischemia leads to loss of this phosphorylation and relocalization of the protein (Lampe et al., 2006) .
In this report, we describe how Cx43 phosphorylation changes as the protein proceeds through its life cycle. Specifically, we show that phosphorylation at S364/S365 leads to P1 formation and phosphorylation at S325/S328/ S330 is necessary for P2 to form. Activation of specific kinases changes the gating properties of gap junction channels, the extent of gap junction assembly, the half-life of Cx43 and, in some cases/cell types, Cx43 electrophoretic mobility. Previously, we showed that activation of protein kinase C (PKC) led to phosphorylation of Cx43 at S368 (Lampe et al., 2000) with a change in electrophoretic mobility in Chinese hamster ovary (CHO), but not normal rat kidney (NRK), cells (Solan et al., 2003) . Here, we show that the change in electrophoretic mobility was apparently due to different pools of Cx43 being phosphorylated on S262 via mitogen-activated protein kinase (MAPK) activation. These results support and refute some of the roles specific kinases and signaling pathways have in the regulation of gap junctional communication and help define the roles that particular phosphorylation events play in regulating the life cycle.
Materials and Methods

Antibodies and Reagents
All general chemicals, unless otherwise noted, were purchased from Fisher Scientific (Pittsburgh, PA). Phorbol 12-myristate 13-acetate (PMA) and a rabbit antibody against Cx43 (C6219) were from Sigma (St. Louis, MO). Mouse anti-Cx43 antibodies Cx43CT1 (referred to as CT) and Cx43IF1 were prepared against amino acids 360-382 of Cx43 and antibody Cx43NT1 against amino acids 1-20 of Cx43 at the Fred Hutchinson Cancer Research Center Hybridoma Development Facility (Seattle, WA). We purchased a phosphospecific antibody to Cx43 at S262 (pS262) from Santa Cruz Biotechnology (Santa Cruz, CA) and a phosphospecific activated MAPK antibody from Cell Signaling Technology (Beverly, MA). We made rabbit anti-pS262, pS279/282, pS368 and pS325/328/330-Cx43 phosphospecific antibodies by custom commercial preparation (ProSci, Poway, CA; 13-week schedule) against synthetic peptides phosphorylated at the specified residues that had been linked via the N-terminal cysteine to maleimide-activated keyhole limpet hemocyanin (Pierce Biotechnology, Rockford, IL); and phosphospecific antibodies were affinity-purified as previously described (Lampe et al., 2006) .
Cell Culture
Madin-Darby canine kidney (MDCK), NRK E51, HeLa and CHO cells were cultured in Dulbecco's minimal essential medium (Fisher Scientific) supplemented with 5-10% fetal calf serum and antibiotics (100 U/ml penicillin G and 100 lg/ml streptomycin) in a humidified 5% CO 2 environment. To make MDCK cells that express wild-type Cx43, pIREShygro Cx43 was electroporated into cells using a Nucleofector apparatus (Amaxa, Gaithersburg, MD). HeLa cells expressing S262A mutant Cx43 were transfected with lipofectamine (Invitrogen, San Diego, CA). In both cases, cells were selected at 500 lg/ml hygromycin B and dilution-cloned in medium supplemented with hygromycin.
Immunoblotting and Immunofluorescence
Whole-cell preparations were lysed in sample buffer supplemented with 50 mM NaF, 1 mM Na 3 VO 4 , 5% b-mercaptoethanol, 1 mM phenylmethyl sulfonyl fluoride and 1x complete protease inhibitors (Roche Molecular Biochemicals, Alameda, CA). Triton insoluble material was collected by centrifugation of cell lysates using 1% Triton X-100 in phosphate-buffered saline with the phosphatase and protease inhibitors listed above. Following sonication in sample buffer, samples were separated by 10% SDS-PAGE. After immunoblotting, protein was detected with rabbit and mouse primary antibodies. Primary antibodies were simultaneously visualized with fluorescent dye-labeled secondary antibodies (AlexaFluor 680 goat antirabbit [Molecular Probes, Eugene, OR] and IRDye800-conjugated donkey anti-mouse IgG [Rockland Immunochemicals, Gilbertsville, PA]) and directly quantified using the LI-COR Biosciences (Lincoln, NE) Odyssey infrared imaging system and associated software.
Results
Formation of the P2 Isoform
As indicated above, Cx43 demonstrates multiple electrophoretic isoforms when analyzed by SDS-PAGE, including a faster-migrating form that includes P0 (or NP) Cx43 and at least two slower-migrating forms, commonly termed P1 and P2 as shown in the first lane (i.e., Ab: Total, Prep: WC) of Figure 1A . Consistent with Musil & Goodenough (1991) , the P2 isoform was insoluble after extraction of cells with Triton X-100, as indicated in the middle lane (Ab: Total, Prep: Tx Ins) of Figure 1A . When that same lane was simultaneously probed with an antibody (pS325) that is specific for Cx43 when it is phosphorylated at S325, S328 and/or S330, we found that only the P2 isoform was present (third lane, Ab: pS325, Prep: Tx Ins). We had previously shown that this phosphospecific antibody labeled the intercalated disk region of cardiomyocytes (Lampe et al., 2006) and that S325/S328/S330 phosphorylation was important in gap junction assembly (Cooper & Lampe, 2002) . In Figure 2B and C, we show that the phosphospecific antibody and an antibody to total Cx43 overlay to a large extent at gap junctional structures but very little at cytoplasmic regions. Close examination of the overlay panel (Fig. 2D) indicates that not all of the apparent junctional material is positive for the pS325 antibody. We conclude that phosphorylation at S325, S328 and/or S330 is specific for gap junctional Cx43 and that these phosphorylation events are likely involved in gap junction assembly.
Formation of the P1 Isoform
We produced a monoclonal antibody named CT that recognizes primarily the P0 isoform of Cx43 ( Fig. 2A , compare lanes 1 and 2). We have epitope-mapped this antibody and found that it binds to Cx43 when it is not phosphorylated at S364 or S365 and, in contrast to the pS325 antibody in Figure 1C , labels almost exclusively cytoplasmic membranes, reminiscent of Golgi staining (Sosinsky et al., 2007) . If we compare the staining pattern of MDCK cells expressing wild-type Cx43 using the CT antibody (mouse) and an antibody to total Cx43 (rabbit), we see essentially complete overlay of the punctate CT staining with the antibody for total Cx43 in cytoplasmic membrane structures reminiscent of the Golgi apparatus and essentially no overlay with the plasma membrane/gap junctional staining observed for the total Cx43 antibody ( Fig. 2A-D) . We conclude that the epitope recognized by the CT antibody is lost (i.e., likely due to phosphorylation) when Cx43 is present in gap junction structures.
Phosphorylation on S262 Creates a Distinct P2 Isoform of Cx43
PMA treatment leads to downregulation of gap junctional communication in many cell types. In some cell types, it also results in a mobility shift of Cx43 to slower-migrating forms. Utilizing several specific Cx43 phosphoantibodies and site-directed mutants with cell lines which do or do not shift, we explored which specific phosphorylation sites might be associated with these events. We examined two cell lines: MDCK cells stably transfected with Cx43, which do not shift in response to PMA, and CHO cells, which do shift. Cells were treated with PMA for 30 min, and immunoblotting was performed using antibodies specific for Cx43 phosphorylated at S368, S262, S279/S282 and S325/S328/S330 (Fig. 3) . Using an antibody to the N terminus of Cx43 which does not discriminate between phosphoforms, we show that MDCK cells do not shift in response to PMA whereas CHO cells show a dramatic increase in the apparent P2 isoform (Fig. 3, Total panel) . This was not due to phosphorylation on S325/S328/S330 as this signal was not apparent in CHO cells at all (probably because most of their Cx43 is in cytoplasmic membranes), nor did it increase in MDCK cells upon PMA treatment (data not shown). In MDCK cells, phosphorylation on S368 can occur on essentially any of the isoforms, including P0, while in CHO cells pS368 was found exclusively on the P2 form (Fig. 3 , compare Total and pS368 panels). In both cell types, phosphorylation on S262 (Fig. 3, pS262 panel) and S279/282 (pS279 panel) was predominantly on the P2 isoform. This could indicate that one or both of these events affects a conformational change resulting in a P2 isoform. To look at this further, we examined the ability of Cx43 mutated at these sites to shift in response to stimuli, both experimentally and in the literature. We have shown previously that HeLa cells expressing wild-type Cx43 or Cx43 with a S368A mutation exhibit a migration shift in response to PMA (Solan et al., 2003) . Here, we show that in HeLa cells expressing a S262A mutant, Cx43 does not shift to the P2 form in response to PMA treatment, although we did observe an apparent shift to a position just above the P0 form (Fig. 3, denoted by asterisks in the lower two panels). Note that the S262A mutants were able to make P2, but since this was present in unstimulated cells, it is likely to represent P2 formed by phosphorylation on S325/S328/S330. When we blotted with the pS279 antibody, we found that phosphorylation on S279/S282 did occur upon PMA treatment and was found on all isoforms except P0. Since p279/282 phosphorylation alone did not lead to formation of the P2 isoform and S262A mutants, which cannot be phosphorylated on this site, did not shift to P2, we conclude that phosphorylation on S262 can lead to a Cx43 isoform which migrates in the P2 position. Furthermore, this P2 species is distinct from P2 phosphorylated on S325/S328/S330 since CHO cells were not phosphorylated on these latter sites.
We feel this provides direct evidence that P2 can be a heterogenous mixture of phosphoforms, some of which are Cx43-phosphorylated at S325/S328/S330, representing the ''classic'' gap junction-associated, Triton X-100-insoluble form of P2 (Musil & Goodenough, 1991) , but some of which are, instead, formed by phosphorylation at S262 and associated with phosphorylation at S279/S282, S262 and S368, which have been linked to decreases in gap junction (pS262) communication (e.g., Doble et al., 2004; Lampe et al., 2000; Warn-Cramer et al., 1996) .
Distinct Pools of Cx43 Are Targeted for Phosphorylation in Different Cell Types
In MDCK cells that make P2 that is phosphorylated at S325/S328/S330 but do not shift in response to PMA, it appears that PMA induced phosphorylation on S262 and S279/S282 specifically on the P2 isoform and not on the P0 form. The rationale behind this is that phosphorylation on S262 does not add to the total amount of P2. However, in CHO cells, which do not assemble junctions very well and make little gap junctional P2, the P0 form seems to become phosphorylated on these sites, resulting in the migration shift and labeling exclusively on the P2 isoform. Note that, similar to MDCK cells, there is a fraction of the CHO P0 form that does not shift or become phosphorylated on these sites (possibly protected in the endoplasmic reticulum), indicating that a pool of Cx43 is refractory to these phosphorylation events.
Phosphorylation on S368 in response to PMA is also differentially regulated. In MDCK cells, essentially all isoforms can become phosphorylated on S368, indicating that this event is independent of S262 or S279/S282 phosphorylation. In CHO cells, pS368 is found only in the P2 form of Cx43, not in the remaining ''unshifted'' P0 isoform. We hypothesize that this ''unshifted'' isoform is the same pool that was refractory to S262 and S279/S282 phosphorylation.
Discussion
There have been many attempts to correlate gap junction function with changes in Cx43 mobility by SDS-PAGE. The reasons for this interest have been multifold, including the fact that mobility changes have been associated with many important disease processes such as hypoxia in cardiac tissue and changes in gap junction function in response to specific stimuli including tumor-promoting and many other drugs. Since different cell types often respond differently to these stimuli, in many cases conflicting data on Cx43 mobility changes made it difficult to draw clear conclusions. This was due both to the fact that different cell lines vary in their ability to assemble and regulate gap junctions and to a lack of understanding of what conformational information was being conveyed by the migration shift. It is important to remember that, though phosphorylation drives the migration change, it presumably is not a molecular weight change that is being detected via SDS-PAGE, since addition of a phosphate would only add 80 Da to the molecular mass, but rather a conformational change in the protein triggered by these phosphorylation events. The development of phosphospecific antibodies is allowing us to more accurately dissect and understand which phosphorylation events and signaling pathways are important in gap junction regulation. Using these tools, we have found several steps in the Cx43 life cycle that can be regulated by phosphorylation in at least some cell types.
Inclusion in the Gap Junction Plaque and Formation of P2
Using a phospho-antibody specific for phosphorylation at S325, S328 and S330, we have shown that these sites are phosphorylated in the gap junction plaque-associated, Triton X-100-insoluble P2 isoform of Cx43. Cells expressing site-directed mutants, in which these serines were converted to alanines, do not assemble gap junctions efficiently or make the P2 isoform of Cx43 (Lampe et al., 2006) . These data indicate that phosphorylation on S325, S328 and/or S330 is required for formation of the gap junction plaque-associated P2 isoform of Cx43 (see model in Fig. 4 ). In addition, previous work from our lab has shown that casein kinase 1 is important for plaque formation as its inhibition led to a decrease in gap junction plaques and an increase in hemichannels in the plasma membrane (Cooper & Lampe, 2002) . Taken together, these data are consistent with the idea that phosphorylation on Fig. 4 Model of how Cx43 phosphorylation at S364/S365 and S325/ S328/S330 could affect the gap junction life cycle. ER, endoplasmic reticulum; CK1, casein kinase 1 some combination of S325/S328/S330 by casein kinase 1 results in a conformational change resulting in the P2 isoform and inclusion in a gap junction plaque.
Transport to the Plasma Membrane and Formation of P1
Use of a monoclonal antibody specific for Cx43 not phosphorylated on S364 or S365, termed ''CT,'' showed that these residues appear to be important for trafficking to the plasma membrane. Immunofluorescence staining showed that this antibody recognized Cx43 in the cytoplasm only and not in the plasma membrane (Fig. 2B-D) , while immunoblots showed that, in resting cells, this antibody recognized primarily the P0 form of Cx43. Cellsurface biotinylation assays showed that essentially all isoforms, including P0, could reach the plasma membrane, while acquisition of Triton X-100 insolubility and inclusion in plaques was correlated with phosphorylation to the P2 form (Musil & Goodenough, 1991) . The functional relevance of the P1 form, however, has not been shown. Interestingly, one feature of the CT antibody is that it never recognizes the P1 form ( Fig. 2 ; Sosinsky et al., 2007) . Since CT recognizes NP S364 and S365 and does not recognize P1, it is likely that phosphorylation on one or both of these residues leads to the P1 isoform.
While the cell-surface biotinylation data indicate that the phosphorylation event leading to the P1 isoform may occur in the plasma membrane (Musil & Goodenough, 1991) , the immunofluorescence data (Fig. 2) indicate that this event is required for trafficking from the cytoplasm to the plasma membrane (Fig. 4) . Since hemichannels are made up of six connexins, it may be that only a fraction of these need be phosphorylated to propel forward trafficking. This would result in the cytoplasmic Cx43 being CTreactive, i.e., not phosphorylated on S364 or S365. The P0 or CT isoform in the plasma membrane could be diffuse and therefore undetectable by immunofluorescence until entering a gap junction plaque, where it would become more concentrated and eventually phosphorylated to the P2 isoform.
Induced Phosphorylation Can Lead to a distinct P2
Treatment of cells with various stimuli can result in a shift of Cx43 to slower-migrating forms and is often associated with downregulation of gap junctional communication. Several studies have focused on using growth factors and PMA in combination with MAPK and PKC inhibitors to correlate changes in Cx43 isoform migration with shutdown of gap junctional communication. In one study, IAR6.1 cells, which endogenously express Cx43 and make P2 in resting cells, exhibited a decrease in gap junctional communication and a migration shift in response to both PMA and epidermal growth factor (EGF) (Rivedal & Opsahl, 2001) . In these cells, inhibition of extracellular signal-regulated kinase (ERK) 1/2, but not of PKC, could inhibit the migration shift in response to PMA and EGF, although it did not reverse PMA-induced inhibition of gap junctional communication. This led the authors to conclude that the migration shift was due to phosphorylation on Cx43 via ERK1/2. However, which sites might be responsible was not determined. The sites where ERK1/2 phosphorylates Cx43 have been determined to be S255, S279 and S282; and when wild-type Cx43 or S279/S282/ S255A mutant Cx43 was expressed in HeLa cells, EGF treatment led to a migration shift in both wild-type and mutant-expressing cells, although inhibition of communication was only observed in wild-type Cx43-expressing cells (Warn-Cramer et al., 1996 . Inhibition of ERK1/2 reversed both of these effects. Both of these studies are consistent with the idea that ERK1/2 activation can lead to P2 formation, although not through phosphorylation on S279 or S282. Interestingly, when we used PD98059, the same ERK1/2 inhibitor used in the studies described above, PMA was able to activate ERK1/2 regardless of the presence of inhibitor, even though ERK1/ 2 were inhibited in resting cells (data not shown). Thus, it seems consistent with the data that S262 is phosphorylated in an ERK1/2-dependent manner and that this event is responsible for the TPA-and EGF-induced mobility shift. While the functional consequences of S262 phosphorylation are not yet clear, it does seem apparent that identification of specific phosphorylation sites and the specific signaling pathways involved will allow us to design pertinent experiments that will allow a greater understanding of gap junction regulation.
